drugset / Trial / NCT00352768

Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents

NCT00352768

Phase 4 Terminated 20 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder

Timeline

Start
2006-08
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown 25 mg Oral